SCHEMBL163411

SCHEMBL163411

O=C(CNc1nccs1)N1CCN(c2ccccc2-c2cccnc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.42
CXCR3 P49682 1/20 0.41
KCNH2 Q12809 1/20 0.41
KDM1A O60341 1/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
CYP46A1 Q9Y6A2 1/20 0.40
GFER P55789 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
P2RX7 Q99572 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 3/20 0.39
NPC1 O15118 1/20 0.39
SMYD2 Q9NRG4 1/20 0.39
GAA P10253 1/20 0.39
SLC6A7 Q99884 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3727130 0.92 CXCR3 (0.48) PTGS2CXCR3KCNH2KMT2ALMNA
SCHEMBL13077192 0.87 KMT2A (0.39) PTGS2CXCR3KCNH2KMT2ALMNA
SCHEMBL115798 0.85 HTR1A (0.42) PTGS2CXCR3KCNH2KMT2ALMNA
SCHEMBL115274 0.84 CHEK1 (0.42) PTGS2CXCR3KCNH2KMT2ALMNA
SCHEMBL114199 0.83 PTGS2 (0.42) PTGS2KMT2ALMNAGFERSMN1; SMN2
SCHEMBL13039588 0.81 CXCR3 (0.49) CXCR3KCNH2KMT2ACYP46A1MEN1
SCHEMBL112087 0.77 CYP1A2 (0.48) KMT2ALMNAGFERMEN1SMN1; SMN2
SCHEMBL165214 0.76 GFER (0.51) CXCR3KCNH2KMT2ALMNAGFER
SCHEMBL3732859 0.75 CXCR3 (0.52) CXCR3KCNH2KMT2ACYP46A1RAB9A
SCHEMBL15911600 0.74 CXCR3 (0.45) CXCR3KCNH2KMT2ALMNAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
EP-2424840-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 PTGS2 872/4885CXCR3 1/4885KCNH2 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.